Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat

Journal of Neuroinflammation

Volumn 2, Issue , 2005, Pages

  Candelario Jalil, Eduardo ^a,b   Mhadu, Noël H ^a   González Falcón, Armando ^a   García Cabrera, Michel ^a   Muñoz, Eduardo ^c   León, Olga Sonia ^a   Fiebich, Bernd L ^b,d  

^a UNIVERSITY OF HAVANA   (Cuba)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d VIVACELL BIOTECHNOLOGY GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NIMESULIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; RAT; ROTAROD TEST; SCORING SYSTEM;

EID: 18144404353     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-2-3     Document Type: Article

References (57)

1. Hankey GJ: Stroke: how large a public health problem, and how can the neurologist help? Arch Neurol 1999, 56: 748-754.
2. Dugan LL, Choi DW: Hypoxic-ischemic brain injury and oxidative stress. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects Sixth edition. Edited by: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. Philadelphia: Lippincott-Raven Publishers; 1999:711-729.
3. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397.
4. Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999, 19: 1213-1219.
5. Nogawa S, Zhang F, Ross ME, Iadecola C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 17:2746-2755.
6. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ: Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000, 10:95-112.
7. Iadecola C, Alexander M: Cerebral ischemia and inflammation. Curr Opin Neurol 2001, 14:89-94.
8. Dore S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, Hurn PD, Traystman RJ, Andreasson K: Neuronal expression of cyclooxygenase-2 increases stroke damage. Ann Neurol 2003, 54:155-162.
9. Tan KT, Lip GY, Blann AD: Post-stroke inflammatory response: effects of stroke evolution and outcome. Curr Atheroscler Rep 2003, 5:245-51.
10. Candelario-Jalil E, Alvarez D, Gonzalez-Falcon A, Garcia-Cabrera M, Martinez-Sanchez G, Merino N, Giuliani A, Leon OS: Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia. Eur J Pharmacol 2002, 453:189-195.
11. Candelario-Jalil E, Alvarez D, Castaneda JM, Al-Dalain SM, Martinez-Sanchez G, Merino N, Leon OS: The highly selective cyclooxygenase-2 inhibitor DFU is neuroprotective when given several hours after transient cerebral ischemia in gerbils. Brain Res 2002, 927:212-215.
12. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL: Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res 2004, 1007:98-108.
13. Cullen L, Kelly L, Connor SO, Fitzgerald DJ: Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 1998, 287:578-582.
14. Taniguchi Y, Yokoyama K, Noda K: Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 1997, 330:221-229.
15. Wakita H, Tomimoto H, Akiguchi I, Lin JX, Miyamoto K, Oka N: A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia. Neuroreport 1999, 10:1461-1465.
16. Candelario-Jalil E, Ajamieh HH, Sam S, Martínez G, León OS: Nimesulide limits kainate-induced oxidative damage in the rat hippocampus. Eur J Pharmacol 2000, 390:295-298.
17. Scali C, Prosperi C, Vannucchi MG, Pepeu G, Casamenti F: Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur J Neurosci 2000, 12:1900-1912.
18. Cernak I, O'Connor C, Vink R: Activation of cyclo-oxygenase-2 contributes to motor and cognitive dysfunction following diffuse traumatic brain injury in rats. Clin Exp Pharmacol Physiol 2001, 28:922-925.
19. Cernak I, O'Connor C, Vink R: Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Exp Brain Res 2002, 147:193-199.
20. Mirjany M, Ho L, Pasinetti GM: Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 2002, 301:494-500.
21. Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti GM: Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol (Berl) 2002, 103:157-162.
22. Candelario-Jalil E, Alvarez D, Merino N, Leon OS: Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils. Neurosci Res 2003, 47:245-253.
23. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R: The "malignant" middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996, 53:309-315.
24. Pantano P, Caramia F, Bozzao L, Dieler C, von Kummer R: Delayed increase in infarct volume after cerebral ischemia: correlation with thrombolytic treatment and clinical outcome. Stroke 1999, 30:502-507.
25. Fisher M: Stroke Therapy. 2nd edition. Butterworth Heineman; 2001.
26. Kassem-Moussa H, Graffagnino C: Nonocclusion and spontaneous recanalization rates in acute ischemic stroke: a review of cerebral angiography studies. Arch Neurol 2002, 59: 1870-1873.
27. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G: Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 1986, 8:1-8.
28. Doerfler A, Schwab S, Hoffmann TT, Engelhorn T, Forsting M: Combination of decompressive craniectomy and mild hypothermia ameliorates infarction volume after permanent focal ischemia in rats. Stroke 2001, 32:2675-2681.
29. Gonzalez-Falcon A, Candelario-Jalil E, Garcia-Cabrera M, Leon OS: Effects of pyruvate administration on infarct volume and neurological deficits following permanent focal cerebral ischemia in rats. Brain Res 2003, 990:1-7.
30. Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
31. Minematsu K, Li L, Sotak CH, Davis MA, Fisher M: Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging in rats. Stroke 1992, 23: 1304-1310.
32. van Lookeren Campagne M, Thibodeaux H, Bruggen N, Cairns B, Gerlai R, Palmer JT, Williams SP, Lowe DG: Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci USA 1999, 96:12870-12875.
33. Callaway JK, Lawrence AJ, Jarrott B: AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology 2003, 44:787-800.
34. Yang Y, Shuaib A, Li Q: Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method. J Neurosci Methods 1998, 84:9-16.
35. Shuaib A, Xu Wang C, Yang T, Noor R: Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002, 33:3033-3037.
36. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A: Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000, 31:1411-1417.
37. Yang Y, Li Q, Miyashita H, Howlett W, Siddiqui M, Shuaib A: Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. J Neurosurg 2000, 92:841-847.
38. Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D: Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood 2001, 97: 3086-3092.
39. Toutain PL, Cester CC, Haak T, Metge S: Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. J Vet Pharmacol Ther 2001, 24:35-42.
40. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD: Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 1996, 27:1616-1623.
41. Abraham H, Somogyvari-Vigh A, Maderdrut JL, Vigh S, Arimura A: Filament size influences temperature changes and brain damage following middle cerebral artery occlusion in rats. Exp Brain Res 2002, 142:131-138.
42. Rudin M, Baumann D, Ekatodramis D, Stirnimann R, McAllister KH, Sauter A: MRI analysis of the changes in apparent water diffusion coefficient, T(2) relaxation time, and cerebral blood flow and volume in the temporal evolution of cerebral infarction following permanent middle cerebral artery occlusion in rats. Exp Neurol 2001, 169:56-63.
43. Hofmeijer J, Veldhuis WB, Schepers J, Nicolay K, Kappelle LJ, Bar PR, van der Worp HB: The time course of ischemic damage and cerebral perfusion in a rat model of space-occupying cerebral infarction. Brain Res 2004,1013:74-82.
44. Hunter AJ, Mackay KB, Rogers DC: To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol Sci 1998, 19:59-66.
45. Stroke Therapy Academy Industry Roundtable (STAIR II): Recommendation for clinical trial evaluation of acute stroke therapies. Stroke 2001, 32:1598-1606.
46. Grotta J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002, 33: 306-307.
47. Lees KR: Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke 2002, 33:308-309.
48. Fisher M, Takano K: The penumbra, therapeutic time window and acute ischaemic stroke. Baillieres Clin Neurol 1995, 4:279-295.
49. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA: Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003, 140:471-6.
50. Gladstone DJ, Black SE, Hakim AM: Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2136.
51. Sasaki T, Kitagawa K, Yamagata K, Takemiya T, Tanaka S, Omura-Matsuoka E, Sugiura S, Matsumoto M, Hori M: Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab 2004, 24:107-113.
52. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C: Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 1998, 95:10966-10971.
53. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Alvarez D, Al-Dalain S, Martinez G, Leon OS, Springer JE: Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 2003, 86:545-555.
54. Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stetler RA, Isakson PC, Chen J, Graham SH: Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998, 95:10954-10959.
55. Sugimoto K, Iadecola C: Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res 2003, 960:273-6.
56. Hirschberg DL, Yoles E, Belkin M, Schwartz M: Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported. J Neuroimmunol 1994, 50:9-16.
57. Dash PK, Mach SA, Moore AN: Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J Neurotrauma 2000, 17:69-81.